Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.
Details : The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-t...
Brand Name : Intrarosa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 08, 2023
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Endoceutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Intrarosa is now available in this market as the first and only locally acting DHEA (dehydroepiandrosterone) treatment indicated for postmenopausal women experiencing moderate to severe symptoms associated with vulvovaginal atrophy (VVA).
Brand Name : Intrarosa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 14, 2022
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Endoceutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Prasterone
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Millicent Pharma Limited
Deal Size : $125.0 million
Deal Type : Divestment
Details : Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $20.0 million
May 21, 2020
Lead Product(s) : Prasterone
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Millicent Pharma Limited
Deal Size : $125.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?